Lessons learned from the clinical development of oral peptides

被引:41
|
作者
Karsdal, Morten Asser [1 ]
Riis, Bente Juul [1 ]
Mehta, Nozer [2 ]
Stern, William [2 ]
Arbit, Ehud [3 ]
Christiansen, Claus [1 ]
Henriksen, Kim [1 ]
机构
[1] Nord Biosci AS, Herlev, Denmark
[2] Enteris Biopharma Inc, Boonton, NJ USA
[3] Oramed Pharmaceut, Jerusalem, Israel
关键词
bone; calcitonin; cartilage; clinical trial; diabetes; oral formulation; GLUCAGON-LIKE PEPTIDE-1; PARATHYROID-HORMONE RHPTH(1-31)NH2; HEALTHY POSTMENOPAUSAL WOMEN; HUMAN GROWTH-HORMONE; PROOF-OF-CONCEPT; IN-VIVO ACTIVITY; SALMON-CALCITONIN; INTESTINAL-ABSORPTION; BONE TURNOVER; FOOD-INTAKE;
D O I
10.1111/bcp.12557
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The oral delivery of peptides and proteins has been hampered by an array of obstacles. However, several promising novel oral delivery systems have been developed. This paper reviews the most advanced oral formulation technologies, and highlights key lessons and implications from studies undertaken to date with these oral formulations. Special interest is given to oral salmon calcitonin (CT), glucagon-like peptide-1 (GLP-1), insulin, PYY-(3-36), recombinant human parathyroid hormone (rhPTH(1-31)-NH2) and PTH(1-34), by different technologies. The issues addressed include (i) interaction with water, (ii) interaction with food, (iii) diurnal variation, (iv) inter- and intra-subject variability, (v) correlation between efficacy and exposure and (vi) key deliverables of different technologies. These key lessons may aid research in the development of other oral formulations.
引用
收藏
页码:720 / 732
页数:13
相关论文
共 50 条
  • [1] Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
    Dijksteel, Gabrielle S.
    Ulrich, Magda M. W.
    Middelkoop, Esther
    Boekema, Bouke K. H. L.
    FRONTIERS IN MICROBIOLOGY, 2021, 12
  • [2] Lessons Learned from the Clinical Development and Market Authorization of Glybera
    Bryant, Laura M.
    Christopher, Devin M.
    Giles, April R.
    Hinderer, Christian
    Rodriguez, Jesse L.
    Smith, Jenessa B.
    Traxler, Elizabeth A.
    Tycko, Josh
    Wojno, Adam P.
    Wilson, James M.
    HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2013, 24 (02) : 55 - 64
  • [3] Lessons Learned From the Development of Oral Calcitonin: The First Tablet Formulation of a Protein in Phase III Clinical Trials
    Karsdal, M. A.
    Henriksen, K.
    Bay-Jensen, A. C.
    Molloy, B.
    Arnold, M.
    John, M. R.
    Byrjalsen, I.
    Azria, M.
    Riis, B. J.
    Qvist, P.
    Christiansen, C.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (04): : 460 - 471
  • [4] Lessons Learned for Collaborative Clinical Content Development
    Collins, S. A.
    Bavuso, K.
    Zuccotti, G.
    Rocha, R. A.
    APPLIED CLINICAL INFORMATICS, 2013, 4 (02): : 304 - 316
  • [5] Clinical software development for the Web: lessons learned from the BOADICEA project
    Alex P Cunningham
    Antonis C Antoniou
    Douglas F Easton
    BMC Medical Informatics and Decision Making, 12
  • [6] Clinical software development for the Web: lessons learned from the BOADICEA project
    Cunningham, Alex P.
    Antoniou, Antonis C.
    Easton, Douglas F.
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2012, 12
  • [7] Lessons learned from a clinical trial
    Armstrong, PW
    Newby, LK
    Granger, CB
    Lee, KL
    Simes, RJ
    Van de Werf, F
    White, HD
    Califf, RM
    CIRCULATION, 2004, 110 (23) : 3610 - 3614
  • [8] Lessons learned from the development of imatinib
    Lydon, NB
    Druker, BJ
    LEUKEMIA RESEARCH, 2004, 28 : S29 - S38
  • [9] Lessons learned from development of docetaxel
    Strother, Robert Matthew
    Sweeney, Christopher
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2008, 4 (07) : 1007 - 1019
  • [10] Clinical delivery of circular RNA: Lessons learned from RNA drug development
    Young, Tiana Loan
    Wang, Kevin Chang
    Varley, Andrew James
    Li, Bowen
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 197